214 related articles for article (PubMed ID: 17311555)
1. Inflammatory caspases: targets for novel therapies.
Cornelis S; Kersse K; Festjens N; Lamkanfi M; Vandenabeele P
Curr Pharm Des; 2007; 13(4):367-85. PubMed ID: 17311555
[TBL] [Abstract][Full Text] [Related]
2. Pralnacasan (vertex pharmaceuticals).
Siegmund B; Zeitz M
IDrugs; 2003 Feb; 6(2):154-8. PubMed ID: 12789619
[TBL] [Abstract][Full Text] [Related]
3. [Caspases--a new target in inflammation and cancer therapy?].
Korzeniewska-Dyl I
Pol Merkur Lekarski; 2008 Jan; 24(139):5-7. PubMed ID: 18634242
[TBL] [Abstract][Full Text] [Related]
4. Caspases: pharmacological manipulation of cell death.
Lavrik IN; Golks A; Krammer PH
J Clin Invest; 2005 Oct; 115(10):2665-72. PubMed ID: 16200200
[TBL] [Abstract][Full Text] [Related]
5. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis.
Rudolphi K; Gerwin N; Verzijl N; van der Kraan P; van den Berg W
Osteoarthritis Cartilage; 2003 Oct; 11(10):738-46. PubMed ID: 13129693
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy.
Ravizza T; Lucas SM; Balosso S; Bernardino L; Ku G; Noé F; Malva J; Randle JC; Allan S; Vezzani A
Epilepsia; 2006 Jul; 47(7):1160-8. PubMed ID: 16886979
[TBL] [Abstract][Full Text] [Related]
7. Natural and synthetic inhibitors of caspases: targets for novel drugs.
Onténiente B
Curr Drug Targets CNS Neurol Disord; 2004 Aug; 3(4):333-40. PubMed ID: 15379609
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs.
Le GT; Abbenante G
Curr Med Chem; 2005; 12(25):2963-77. PubMed ID: 16378499
[TBL] [Abstract][Full Text] [Related]
9. Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases.
Kent CR; Bryja M; Gustafson HA; Kawarski MY; Lenti G; Pierce EN; Knopp RC; Ceja V; Pati B; Walters DE; Karver CE
Bioorg Med Chem Lett; 2016 Nov; 26(22):5476-5480. PubMed ID: 27777011
[TBL] [Abstract][Full Text] [Related]
10. Current opinion on 3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]- 4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid, an investigational drug targeting caspases and caspase-like proteases: the clinical trials in sight and recent anti-inflammatory advances.
Haddad JJ
Recent Pat Inflamm Allergy Drug Discov; 2013 Sep; 7(3):229-58. PubMed ID: 23859695
[TBL] [Abstract][Full Text] [Related]
11. The use of salt-inducible kinase inhibitors to treat autoimmune and inflammatory diseases: evaluation of WO2013136070.
Norman P
Expert Opin Ther Pat; 2014 Aug; 24(8):943-6. PubMed ID: 24745372
[TBL] [Abstract][Full Text] [Related]
12. Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery.
Talanian RV; Brady KD; Cryns VL
J Med Chem; 2000 Sep; 43(18):3351-71. PubMed ID: 10978183
[No Abstract] [Full Text] [Related]
13. Caspases: structure-guided design of drugs to control cell death.
Weber IT; Fang B; Agniswamy J
Mini Rev Med Chem; 2008 Oct; 8(11):1154-62. PubMed ID: 18855730
[TBL] [Abstract][Full Text] [Related]
14. The potential for caspases in drug discovery.
MacKenzie SH; Schipper JL; Clark AC
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):568-76. PubMed ID: 20812148
[TBL] [Abstract][Full Text] [Related]
15. Structure-based combinatorial library design: discovery of non-peptidic inhibitors of caspases 3 and 8.
Head MS; Ryan MD; Lee D; Feng Y; Janson CA; Concha NO; Keller PM; deWolf WE
J Comput Aided Mol Des; 2001 Dec; 15(12):1105-17. PubMed ID: 12160093
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives.
Soltani A; Bahreyni A; Boroumand N; Roshan MK; Khazaei M; Ryzhikov M; Soleimanpour S; Avan A; Hassanian SM
J Cell Physiol; 2018 Jun; 233(6):4783-4790. PubMed ID: 29165795
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological caspase inhibitors: research towards therapeutic perspectives.
Kudelova J; Fleischmannova J; Adamova E; Matalova E
J Physiol Pharmacol; 2015 Aug; 66(4):473-82. PubMed ID: 26348072
[TBL] [Abstract][Full Text] [Related]
18. Caspase substrates and inhibitors.
Poreba M; Strózyk A; Salvesen GS; Drag M
Cold Spring Harb Perspect Biol; 2013 Aug; 5(8):a008680. PubMed ID: 23788633
[TBL] [Abstract][Full Text] [Related]
19. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury.
Festoff BW; Ameenuddin S; Arnold PM; Wong A; Santacruz KS; Citron BA
J Neurochem; 2006 Jun; 97(5):1314-26. PubMed ID: 16638021
[TBL] [Abstract][Full Text] [Related]
20. Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases.
Szollosi DE; Manzoor MK; Aquilato A; Jackson P; Ghoneim OM; Edafiogho IO
J Pharm Pharmacol; 2018 Jan; 70(1):18-26. PubMed ID: 28872680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
